William Chase - AbbVie President

ABBV Stock  USD 180.52  0.17  0.09%   

President

Mr. William J. Chase serves as Executive Vice President Finance and Administration of the Company. He served as Abbott Vice President, Licensing and Acquisitions from 2010 to 2012, as Vice President, Treasurer from 2007 to 2010, and as Divisional Vice President, Controller of Abbott International from 2004 to 2007. Mr. Chase joined Abbott in 1989. since 2018.
Age 50
Tenure 6 years
Address 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Phone847 932 7900
Webhttps://www.abbvie.com

AbbVie Management Efficiency

The company has return on total asset (ROA) of 0.0807 % which means that it generated a profit of $0.0807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.352 %, meaning that it created $0.352 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.65 in 2024, whereas Return On Assets are likely to drop 0.03 in 2024. At this time, AbbVie's Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 6.9 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 57.7 B in 2024.
The company currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist AbbVie until it has trouble settling it off, either with new capital or with free cash flow. So, AbbVie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AbbVie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AbbVie to invest in growth at high rates of return. When we think about AbbVie's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

PRESIDENT Age

Dominique GrauAgilent Technologies
65
Patrick KaltenbachAgilent Technologies
53
Rodney GonsalvesAgilent Technologies
58
Bruce CFAEquillium
58
Alicia RodriguezAgilent Technologies
N/A
Michael TangAgilent Technologies
50
Jacob ThaysenAgilent Technologies
49
Eilon AsculaiMediwound
N/A
Bruce SteelEquillium
50
Samraat RahaAgilent Technologies
51
Mark DoakAgilent Technologies
63
Henrik AncherJensenAgilent Technologies
59
Robert McMahonAgilent Technologies
55
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 50000 people. AbbVie Inc (ABBV) is traded on New York Stock Exchange in USA. It is located in 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 and employs 50,000 people. AbbVie is listed under Biotechnology category by Fama And French industry classification.

Management Performance

AbbVie Inc Leadership Team

Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
Azita Gerhardt, Executive Vice President - Operations
Carlos Alban, Vice Chairman, Chief Commercial Officer
Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer
Jeffrey Stewart, Executive Vice President, Chief Commercial Officer
Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics
Brett Hart, Independent Director
William Chase, Executive Vice President - Finance and Administration
Roxanne Austin, Independent Director
Perry Siatis, General VP
Azita SalekiGerhardt, Executive Vice President - Operations
Scott Reents, Executive CFO
Thomas Freyman, Independent Director
Thomas MD, Senior Research
Edward Rapp, Independent Director
Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee
Tracie Haas, Brand Responsibility
Sanjay Narayan, Chief SVP
Brian Durkin, Vice President Controller
Thomas Hurwich, Vice President Controller
Frederick Waddell, Independent Director
Robert Alpern, Independent Director
Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer
Glenn Tilton, Lead Independent Director
Assil Omar, VP Officer
Greg Miley, Senior Affairs
Henry Gosebruch, Executive Vice President Chief Strategy Officer
Elizabeth Shea, Senior Relations
Rebecca Roberts, Independent Director
Edward Liddy, Independent Director
William Burnside, Independent Director
Elaine Sorg, Senior Vice President U.S. Commercial Operations
WulffErik Borcke, Senior Oncology
Timothy Richmond, Chief Human Resource Officer, Executive Vice President
Nicholas Donoghoe, Senior Vice President - Enterprise Innovation
Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary
Roy Roberts, Independent Director
Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer
Melody Meyer, Independent Director

AbbVie Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with AbbVie

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.

Moving together with AbbVie Stock

  0.89EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against AbbVie Stock

  0.9MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.9VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.82KA Kineta Inc Report 29th of March 2024 PairCorr
  0.81CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
  0.8DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's future performance. For an informed investment choice regarding AbbVie Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for AbbVie Stock analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.67)
Dividend Share
5.99
Earnings Share
2.72
Revenue Per Share
30.723
Quarterly Revenue Growth
(0.05)
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.